ACTA ORTHOPAEDICA ET TRAUMATOLOGICA TURCICA, cilt.49, sa.1, ss.67-74, 2015 (SCI-Expanded, Scopus, TRDizin)
Objective: The aim of this study was to examine the level of compliance and persistence in patients with postmenopausal osteoporosis (OP) receiving daily risedronate (5 mg) with either fixed dosing of three different timing regimens (A: before breakfast; B: in-between meals; C: before bedtime) or with flexible dosing and the effect on urinary N-terminal telopeptide of Type 1 collagen (NTX-1).